The Great Medicare GLP-1 Gamble

If you've been reading Drugstore Cowboy for a while, you've watched the GLP-1 story evolve in real time.

We've talked about shortages.

We've talked about compounded knockoffs.

We've talked about oral GLP-1s, Chinese supply chains, telehealth startups, pharmacy reimbursement disasters, and the rise of direct-to-consumer programs like LillyDirect and NovoCare.

Through all of it, one question has lingered in the background:

Who is ultimately going to pay for all of this?

Starting July 1st, we're about to get an answer.

Millions of Medicare beneficiaries will become eligible to receive GLP-1 medications specifically for obesity treatment through a new federal program called the Medicare GLP-1 Bridge Program.

For patients, the headline is simple:

$50 per month.

For taxpayers, things get a lot more complicated.

And depending on how this experiment unfolds, it could either become one of the smartest healthcare investments in modern American history or one of the most expensive.

Let's talk about it.

The first thing to understand is that Medicare already covers GLP-1 medications in many situations.

If a patient has diabetes, cardiovascular disease, sleep apnea, or certain other qualifying conditions, Medicare may already pay for drugs like Wegovy, Zepbound, or other GLP-1s. Millions of beneficiaries already receive these medications through those pathways.

What Medicare generally does not cover is obesity treatment by itself.

That's because federal law specifically prohibits Medicare from covering medications prescribed solely for weight loss.

Which makes what happens on July 1st a little complicated.

Rather than changing the law, the federal government has created a temporary demonstration project that effectively sidesteps it. The Medicare GLP-1 Bridge Program will run from July 1 2026 through December 31 2027 and allow eligible beneficiaries to receive obesity medications at a flat monthly cost of $50.

In plain English:

Medicare technically still doesn't cover weight-loss drugs.

But starting July 1st, Medicare is going to pay for weight-loss drugs.

Welcome to American healthcare.

When I first started reading about the Bridge Program, I assumed these drugs would simply be added to Medicare Part D.

They aren't.

The entire program exists outside the traditional Medicare prescription drug benefit. Physicians will submit prior authorization requests through a separate process, approved patients can fill prescriptions at participating pharmacies, and Humana will administer much of the program by adjudicating the claims separate from a patient’s regular insurance plan.

The $50 monthly copay also sits completely outside the normal Part D structure.

It doesn't count toward Part D deductibles.

It doesn't count toward Part D out-of-pocket spending limits.

Even patients who qualify for Medicare's Extra Help program still owe the same $50 monthly copay.

The arrangement is unusual enough that I initially assumed I had misunderstood it.

But that's really how it works.

The government has effectively created a parallel prescription benefit to test whether broad obesity treatment makes economic sense.

Which brings us to the obvious question.

The answer is unsurprisingly unsatisfying.

Nobody knows.

The Centers for Medicare and Medicaid Services has repeatedly declined to publicly release cost estimates for the program. Even after multiple requests from reporters, the agency has not disclosed what its own experts believe taxpayers should expect to spend.

That strikes me as odd.

If you're about to launch a nationwide healthcare initiative involving one of the most popular drug classes in modern history, most people would expect somebody to have at least a rough estimate of the bill.

Instead, we're left with educated guesses.

The Congressional Budget Office estimates that roughly 29 million Medicare beneficiaries could qualify for GLP-1 coverage under expanded obesity eligibility criteria. Of those, about 16 million already qualify through existing conditions such as diabetes or cardiovascular disease. That leaves approximately 13 million beneficiaries who could become newly eligible because of obesity alone.

The government's share of the cost is expected to be approximately $195 per patient per month after accounting for the patient's $50 copay.

If every eligible beneficiary enrolled, annual taxpayer spending on the program could exceed $30 billion.

That's more than NASA's annual budget.

No one expects enrollment to reach that level.

But even modest participation creates enormous spending.

Analysts estimate that if just 10% of newly eligible beneficiaries participate, taxpayer spending could still approach $3 billion annually.

The range is so wide because nobody knows how many people will actually sign up.

And that's what makes this such a fascinating policy experiment.

For the past three years, the GLP-1 conversation has mostly been about access.

Patients wanted coverage.

Doctors wanted fewer restrictions.

Manufacturers wanted broader adoption.

Employers worried about costs.

Everyone argued about whether these medications should be available.

We're entering a different phase now.

The question is no longer whether these drugs work or who should have access to them.

The question is who should pay for them.

And unlike many healthcare debates, there are compelling arguments on both sides.

The case for the program is straightforward.

Obesity contributes to diabetes, cardiovascular disease, sleep apnea, joint disease, and countless other costly chronic conditions. GLP-1 medications have consistently demonstrated an ability to reduce weight and improve important health outcomes.

If widespread obesity treatment prevents enough hospitalizations, strokes, heart attacks, and diabetes complications, taxpayers could ultimately save money.

It's entirely possible that economists will eventually look back on this program the same way we now view smoking cessation programs or blood pressure treatment: expensive upfront, but enormously beneficial over time.

The opposing argument is equally straightforward.

These drugs are expensive.

The eligible population is massive.

And the government is launching the program before anyone can confidently estimate either participation rates or long-term savings.

If utilization explodes and the projected downstream savings never arrive, taxpayers may simply be moving billions of dollars into the pockets of pharmaceutical manufacturers.

And most of that money will ultimately flow to two companies:

Eli Lilly and Novo Nordisk.

What fascinates me about this program is that both outcomes seem plausible.

If widespread obesity treatment prevents enough diabetes, heart disease, and hospitalization, taxpayers may eventually save money.

If adoption explodes and the downstream savings fail to materialize, we may simply be witnessing one of the largest transfers of taxpayer dollars into the pharmaceutical industry ever attempted.

Both outcomes are possible.

And unlike most healthcare debates, we're eventually going to get an answer.

Starting July 1, the federal government will begin testing a simple hypothesis:

If we pay for people to lose weight today, will we spend less treating disease tomorrow?

The answer could reshape Medicare – and medicine – for decades.

Get your boots on. The experiment begins July 1.

Alec Wade Ginsberg, PharmD, RPh
4th-Gen Pharmacist | Owner & COO, C.O. Bigelow
Founder, Drugstore Cowboy